Back to Search
GEOFFREY SCHREINER, MD, MPH
MD, MPH
Pediatrics Physician
NPI: 1437560786Individual
Specialties, Licenses & Credentials
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
277981(MA)
Research & Publications (20)
Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed.
PMID 18091407·Crit Pathw Cardiol·2007
3-trial
Decreasing the use of mechanical restraints and locked seclusion.
PMID 15478875·Adm Policy Ment Health·2004
8-other
B-type natriuretic peptide for the treatment of congestive heart failure.
PMID 11950624·Curr Opin Pharmacol·2002
6-review
Role of the microvascular endothelium in progressive renal disease.
PMID 11856789·J Am Soc Nephrol·2002
6-review
Improvement of human islet cryopreservation by a p38 MAPK inhibitor.
PMID 17331110·Am J Transplant·2007
7-preclinical
Evidence for functional heterogeneity of circulating B-type natriuretic peptide.
PMID 17349887·J Am Coll Cardiol·2007
8-other
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia.
PMID 17724276·Hypertension·2007
7-preclinical
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.
PMID 16857807·Clin Cancer Res·2006
7-preclinical
Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
PMID 16600214·Exp Cell Res·2006
7-preclinical
Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes.
PMID 16603672·J Pharmacol Exp Ther·2006
4-observational
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
PMID 16617327·Leukemia·2006
4-observational
Selective inhibition of p38alpha MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury.
PMID 16751295·Am J Physiol Heart Circ Physiol·2006
7-preclinical
Vascular endothelial growth factor administration does not improve microvascular disease in the salt-dependent phase of post-angiotensin II hypertension.
PMID 16804104·Am J Physiol Renal Physiol·2006
7-preclinical
Affymetrix oligonucleotide analysis of gene expression in the injured heart.
PMID 16010026·Methods Mol Med·2005
6-review
Inhibition of p38 mitogen-activated protein kinase protects human islets from cryoinjury and improves the yield, viability, and quality of frozen-thawed islets.
PMID 16298615·Transplant Proc·2005
8-other
Role of ERK1/2 and p38 mitogen-activated protein kinases in the regulation of thrombospondin-1 by TGF-beta1 in rat proximal tubular cells and mouse fibroblasts.
PMID 15716330·J Am Soc Nephrol·2005
7-preclinical
p38 alpha mitogen-activated protein kinase inhibition improves cardiac function and reduces myocardial damage in isoproterenol-induced acute myocardial injury in rats.
PMID 15454858·J Cardiovasc Pharmacol·2004
4-observational
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
PMID 15480425·Oncogene·2004
8-other
p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells.
PMID 15572041·J Mol Cell Cardiol·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 300 LONGWOOD AVE
BOSTON, MA 02115 - Phone
- (617) 355-6000
Quick Facts
- NPI
- 1437560786
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile